Trader consensus on Polymarket prices "No" at 83.5% for a new COVID variant of concern before 2027, driven by health authorities like WHO and ECDC declining to elevate recent subvariants to VOC status despite close monitoring. The emergence of highly mutated BA.3.2, dubbed "Cicada," first detected in late 2025 and spreading to 29 U.S. states by early April 2026, sparked brief attention for potential immune escape, but its tiny prevalence—under 0.2% of sequences—and lack of increased severity or hospitalizations have eased concerns. Robust global surveillance, hybrid immunity from vaccines targeting JN.1 lineages, and Omicron dominance signal low risk of meeting strict VOC thresholds like transmissibility or public health impact, though unexpected surges could shift odds.